01—Abstract
Summary
Summary of the 8-K filed November 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) filed this Form 8-K on November 24, 2025 to report the appointment of Victor Bulto to its Board of Directors.
The Board appointed Mr. Bulto on November 20, 2025, with his board service effective December 1, 2025. He will receive compensation consistent with the Company's director compensation program, as described in its most recent proxy statement filed April 4, 2025. Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, roles he has held since April 2022.
The filing describes more than two decades of senior Novartis experience across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. The accompanying press release states that he oversees a U.S. business of more than $20 billiona across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic therapeutic areas.
The filing is a governance update with no financial results, guidance, or transaction disclosed. Chairman and CEO Adam Schechter is quoted as saying Bulto's experience will support the Company's strategic priorities, particularly around science, technology, and customer value.
02—Key points
Key Highlights
- Victor Bulto appointed to the Labcorp Board of Directors by the Board on November 20, 2025, effective December 1, 2025.
- Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in both roles since April 2022.
- Bulto's Novartis career spans more than two decades, including President of U.S. Pharmaceuticals and Head of U.S. Alcon Pharmaceuticals.
- Board compensation follows the director compensation program described in the proxy statement filed April 4, 2025.
- The press release says Bulto oversees a U.S. business of more than $20 billion across four therapeutic areas.
- The filing reports no financial results, guidance, or transactions; it is a governance announcement.
- Chairman and CEO Adam Schechter cites Bulto's pharmaceutical and therapeutic-area expertise as relevant to Labcorp's strategic priorities.
03—Questions
Frequently Asked Questions
When does Victor Bulto's board appointment take effect?
The Board appointed Mr. Bulto on November 20, 2025, and his appointment is effective December 1, 2025.
What compensation will Victor Bulto receive as a director?
The filing states he will be compensated for his board service consistent with Labcorp's director compensation program, as described in the proxy statement filed April 4, 2025.
What is Victor Bulto's current role?
He is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in both roles since April 2022.
Does this filing include financial results or guidance?
No. The filing covers only the board appointment and the related press release announcing it.
Why is Labcorp adding a pharmaceutical executive to its board?
CEO Adam Schechter said Bulto's experience leading a large pharmaceutical business and his expertise across key therapeutic areas will help Labcorp advance its strategic priorities around science, technology, and value for customers and shareholders.
04—Continue